Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tarrant O McPherson

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Clinical Neuromuscular Disease|May 23, 2023
Attitudes and Beliefs Toward Thymectomy in the Myasthenia Gravis Patient RegistryAli G Hamedani, Tarrant O McPherson, Inmaculada Aban, et al.
Clinical Gerontologist|April 29, 2017
Neurocognitive Predictors of Declining Financial Capacity in Persons with Mild Cognitive ImpairmentLindsay M Niccolai, Kristen L Triebel, Adam Gerstenecker, et al.
Annals of Neurology|August 28, 2023
Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT TrialElizabeth Martina Bebin, Jurriaan M Peters, Brenda E Porter, et al.
Pediatric Neurology|August 14, 2024
Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) TrialLaura S Farach, Melissa A Richard, Aynara C Wulsin, et al.
Pediatric Neurology|October 8, 2025
Neurodevelopmental Outcomes From the PREVeNT TrialSarah E O'Kelley, Jamie K Capal, Tarrant O McPherson, et al.
Pediatric Neurology|March 29, 2026
Early Vigabatrin Treatment Before Seizure Onset Decreased Interictal Epileptiform Discharges Over the Duration of the PREVeNT StudyTarrant O McPherson, E Martina Bebin, Laura S Farach, et al.
Science Translational Medicine|September 3, 2025
The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteinsSanjeev Kumar, Shilpi Jain, Bushra Wali, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Clinical Neuromuscular Disease|May 23, 2023
Attitudes and Beliefs Toward Thymectomy in the Myasthenia Gravis Patient RegistryAli G Hamedani, Tarrant O McPherson, Inmaculada Aban, et al.
Clinical Gerontologist|April 29, 2017
Neurocognitive Predictors of Declining Financial Capacity in Persons with Mild Cognitive ImpairmentLindsay M Niccolai, Kristen L Triebel, Adam Gerstenecker, et al.
Annals of Neurology|August 28, 2023
Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT TrialElizabeth Martina Bebin, Jurriaan M Peters, Brenda E Porter, et al.
Pediatric Neurology|August 14, 2024
Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) TrialLaura S Farach, Melissa A Richard, Aynara C Wulsin, et al.
Pediatric Neurology|October 8, 2025
Neurodevelopmental Outcomes From the PREVeNT TrialSarah E O'Kelley, Jamie K Capal, Tarrant O McPherson, et al.
Pediatric Neurology|March 29, 2026
Early Vigabatrin Treatment Before Seizure Onset Decreased Interictal Epileptiform Discharges Over the Duration of the PREVeNT StudyTarrant O McPherson, E Martina Bebin, Laura S Farach, et al.
Science Translational Medicine|September 3, 2025
The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteinsSanjeev Kumar, Shilpi Jain, Bushra Wali, et al.
Pageof 1